dabrafenib
Tafinlar
Pharmaceutical company: Novartis
INDICATION & DOSAGE
In combination with trametinib for the treatment of low-grade glioma in patients with a BRAF V600E mutation who require systemic therapy
Children ages 1 to 17 weighing 51 kg or more: 150-mg capsules or suspension PO b.i.d.
Children ages 1 to 17 weighing 38 to 50 kg: 100-mg capsules PO b.i.d.
Children ages 1 to 17 weighing at least 26 to 37 kg: 75-mg capsules PO b.i.d.
Children ages 1 to 17 weighing 8 to 50 kg: 20- to 130-mg oral solution PO b.i.d. based on body weight. See the manufacturer's instructions for recommended dosage table.
Adjust-a-dose: Refer to trametinib prescribing information for recommended dosing information. Refer to the manufacturer's instructions for toxicity-related dosage adjustments. Continue treatment until disease progression or unacceptable toxicity.
Released: May 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
maralixibat
Livmarli
Pharmaceutical company: Mirum Pharmaceuticals
INDICATION & DOSAGE
Cholestatic pruritus in patients with Alagille syndrome
Children age 3 months and older: Initially, 190 mcg/kg PO once daily. After 1 week, increase dosage to 380 mcg/kg once daily as tolerated. Maximum dose is 28.5 mg (3 mL) daily in patients weighing 70 kg or more.
Adjust-a-dose: Decrease dosage or interrupt therapy for liver function test (LFT) abnormalities or GI adverse reactions. When LFT values return to baseline or stabilize at new baseline values, consider restarting at 190 mcg/kg, and increase as tolerated. If LFT abnormalities or GI reactions recur, or signs and symptoms consistent with clinical hepatitis, portal hypertension, or hepatic decompensation (variceal hemorrhage, ascites, hepatic encephalopathy) occur, discontinue therapy.
Released: May 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
sarilumabx
Kevzara
Pharmaceutical company: Sanofi-Aventis and Regeneron Pharmaceuticals
INDICATION & DOSAGE
Polymyalgia rheumatica in patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper
Adults: 200 mg subcut once every 2 weeks in combination with a tapering course of corticosteroids or as monotherapy following discontinuation of corticosteroids.
Adjust-a-dose: Discontinue the drug for ANC below 1,000/mm3, platelet count below 100,000 mm3, or AST or ALT levels above three times the upper limit of normal. Withhold treatment until infection is controlled if serious or opportunistic infection occurs.
Released: May 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
trametinib dimethyl sulfoxide
Mekinist
Pharmaceutical company: Novartis
NEW FORMULATION
Oral solution: 0.05 mg/1 mL
INDICATION & DOSAGE
In combination with dabrafenib for treatment of low-grade glioma with a BRAF V600E mutation in patients who require systemic therapy
Children ages 1 to 17 weighing 51 kg or more: 2-mg tablet or solution PO daily.
Children ages 1 to 17 weighing 38 to 50 kg: 1.5-mg tablet PO once daily.
Children ages 1 to 17 weighing 26 to 37 kg: 1-mg tablet PO once daily.
Children ages 1 to 17 weighing 8 to 50 kg: 0.3- to 1.6-mg oral solution PO daily based on body weight. See manufacturer's instructions for recommended dosage table.
Adjust-a-dose: Refer to the dabrafenib prescribing information for recommended dosing information. Refer to the manufacturer's instructions for toxicity-related dosage adjustments. Continue treatment until disease progression or unacceptable toxicity.
Released: May 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer